Frost & Sullivan Independent Equity Research
Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged.
![logo_cellect-biotech logo_cellect-biotech](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/logo_cellect-biotech-nx7oenqvj2y33m2uhxiuo5wv2s7xme8mc1ykanhgzk.jpg)
Company: Cellect Biotechnology Ltd.
Sector: Biotechnology
Report type: Quarterly Update
Published on: August 30th, 2017